|

The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

RECRUITINGN/ASponsored by Samsung Medical Center
Actively Recruiting
PhaseN/A
SponsorSamsung Medical Center
Started2024-03-18
Est. completion2025-01-15
Eligibility
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06330012

Summary

This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.

Eligibility

Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* HER2 positive breast cancer
* Stage IV disease
* Treated with T-Dxd
* Available FFPE samples

Exclusion Criteria:

* TNBC breast cancer
* Hormone receptor positive breast cancer
* Non-available FFPE samples
* Treated except T-Dxd

Conditions3

Breast CancerCancerHER2-positive Breast Cancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.